Full Press Release Details
Melbourne (Australia) | 16 October 2024
Telix today announces thirteen abstract presentations featuring the Company’s ongoing theranostic development, medical technologies (MedTech), and research and innovation (R&I) programs at the 37 th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Hamburg from 19 – 23 October 2024.
Telix’s extensive theranostic pipeline will be showcased in presentations covering: TLX250-CDx (Zircaix® 1 , 89 Zr-girentuximab) kidney cancer imaging, including first real-world clinical experience; TLX101 ( 131 I-iodofalan or 131 I-IPA) glioblastoma therapy; TLX66 ( 90 Y-besilesomab) bone marrow conditioning therapy; TLX252 ( 225 Ac-girentuximab) carbonic anhydrase IX (CAIX)-targeted alpha therapy; and SENSEI®, Lightpoint’s robotic-assisted gamma probe.
Dr. David N. Cade, Telix Group Chief Medical Officer, said, “We are pleased to be able to so comprehensively showcase our pipeline at EANM – the largest gathering of nuclear medicine professionals worldwide – with a sponsored symposium, and abstracts accepted across Telix’s late-stage theranostic programs in kidney and brain cancers, and in bone marrow conditioning. As in previous years, it is an honour for us to support the EANM Sanjiv Sam Gambhir Young Investigator Award. This is an exciting opportunity for a junior physician or scientist to further develop their career in radiopharmaceuticals, in memory of an extraordinary man and an inspiring educator.”
We look forward to seeing delegates at Telix’s booth in Hall H, Stand H29 to discuss Telix’s industry leading theranostic pipeline in urologic oncology (prostate, kidney and bladder cancers), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and hematology, our associated medical devices, and opportunities for collaboration.
View the EANM symposium and presentation details here
To view the full media release click here
Telix’s lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved in Australia, Canada and the United States for PET imaging of prostate cancer. No other Telix product has received a marketing authorisation in any jurisdiction. Zircaix brand name is subject to final regulatory approval.”